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Abstract 
The acronym THERANOSTICS epitomizes the inseparability of diagnosis and therapy, the 
pillars of medicine and takes into account personalized management of disease for a specific 
patient. Molecular phenotypes of neoplasms can be determined by molecular imaging with 
specific probes using positron emission tomography (PET), single photon emission computed 
tomography (SPECT), magnetic resonance imaging (MRI), or optical methods, so that the 
treatment is specifically targeted against the tumor and its environment. To meet these 
demands, we need to define the targets, ligands, coupling and labeling chemistry, the most 
appropriate radionuclides, biodistribution modifiers, and finally select the right patients for 
the personalized treatment. THERANOSTICS of neuroendocrine tumors (NETs) using Ga-68 
labeled tracers for diagnostics with positron emission tomography/ computed tomography 
(PET/CT), and using Lu-177 or other metallic radionuclides for radionuclide therapy by ap-
plying the same peptide proves that personalized radionuclide therapy today is already a fact 
and not a fiction. 
Key words: THERANOSTICS, molecular imaging, personalized radionuclide therapy. 
INTRODUCTION 
The term  theranostics epitomizes  the insepara-
bility of diagnosis and therapy, the pillars of medi-
cine. In the context of nuclear medicine, it refers to the 
use of molecular targeting vectors (e.g. peptides) la-
beled either with diagnostic radionuclides (e.g. posi-
tron or gamma emitters), or with therapeutic radio-
nuclides for diagnosis and therapy respectively of a 
particular disease, targeted specifically by the vector 
at  its  molecular  level.  Therefore  molecular  imaging 
and  diagnosis  of  the  disease  can  be  effectively  fol-
lowed by personalized treatment utilizing the same 
molecular imaging vectors. One of the classic exam-
ples of theranostics is the use of Ga-68 labeled tracers, 
wherein  the  diagnosis  using  this  generator-derived 
radionuclide can be effectively followed by the ther-
apy using therapeutic radionuclides like Lu-177 and 
Y-90  labeled  with  the  same  tracer  for  personalized 
radionuclide therapy. Addition of two important fac-
ets namely individualized patient dosimetry by pre- 
or post therapeutic imaging, and assessment of ther-
apy  response  using  quantitative  imaging  by  Ga-68 
positron emission tomography/ computed tomogra-
phy  (PET/CT)  fulfills  the  potential  of  personalized 
medicine.  
Ga-68  is  an  easily-available  generator-derived 
diagnostic  trivalent  radio  metal  with  convenient  la-
Ivyspring  
International Publisher   Theranostics 2012, 2(5) 
 
http://www.thno.org 
438 
beling characteristics.1 Ga-68 is prepared from a TiO2 
based  Ge-68/Ga-68  generator  system,  which  has  a 
half-life of 288 days.2 A GMP compliant, fully auto-
mated click and start cassette-based synthesis system 
with easy handling is now available (EZAG, Berlin, 
Germany) for the daily routine production of Ga-68 
labeled  radiopharmaceuticals.  Post-processing  of 
Ge-68/Ga-68  radionuclide  generators  using  cation 
exchange  resin  provides  chemically  and  ra-
dio-chemically  pure  Ga-68  (97±2%)  within  few 
minutes ready for on-site labeling with high overall 
product yields. The single most imperative aspect of 
PET/CT is its ability to quantify the disease at a mo-
lecular level; for a quantitative approach, Ga-68 and 
PET/CT is clearly superior to gamma-emitting radi-
onuclides and single photon emission computed to-
mography (SPECT). Since its first clinical use at our 
centre in July 2004, there has been a tremendous in-
crease in the number of studies with Ga-68, demon-
strating  its  potential  to  become  the  Tc-99m  for 
PET/CT. 
THERANOSTICS OF NETs 
Neuroendocrine  tumors  (NETs)  are  essentially 
characterized  by  their  endocrine  metabolism  and  a 
distinct  histological  pattern.  The  heterogeneous  na-
ture,  frequently  indolent  course  and  possibility  of 
multiple and variable anatomic sites of the primary 
tumor  make  it  difficult  to  evaluate  patients  with 
NETs. Most differentiated NETs over-express soma-
tostatin  receptors  (SSTRs).  Somatostatin  receptor 
scintigraphy (SRS) using In-111 penetreotide has been 
used for the diagnosis of NETs.3,4 However, the de-
velopment of novel somatostatin analogs for labeling 
with Ga-68 and also  with therapeutic radionuclides 
like Lu-177 and Y-90 has enabled highly specific tar-
geting  of  NETs  for  theranostics.  The  Ga-68  labeled 
DOTA-peptides binding to SSTRs with high affinity, 
which  have  been  used  in  the  clinical  setting,  are 
DOTA-D-Phe1-Tyr3-octreotide  (DOTATOC),  DOTA- 
1-Nal3-octreotide  (DOTANOC)  and 
DOTA-D-Phe1-Tyr3-Thr8-octreotide  (DOTATATE). 
Previous studies have established the efficacy of these 
Ga-68  labeled  DOTA-peptides  in  the  diagnosis  of 
NETs.5-9 
In a recent study in normal human tissues, the 
maximum SUV (SUVmax) of Ga-68 DOTATOC has 
been related to the expression of SSTR2 at the level of 
mRNA.  This  was  a  highly  interesting  observation 
demonstrating the real power of molecular imaging, 
and may improve diagnostics, monitoring and ther-
apy of SSTR-expressing tumors on a molecular basis.10 
Our own recent study provided for the first time, the 
proof of concept of the utility of Ga-68 somatostatin 
receptor PET/CT (SSTR PET/CT) for quantification of 
the SSTR density on tumor cells, showing a close cor-
relation between maximum SUV and immunohisto-
chemical scores used for the quantitative assessment 
of the density of subtypes of SSTRs in NET tissue.11 
Ten years ago, Hofmann et al. have shown for 
the  first  time  that  Ga-68  DOTATOC  is  superior  to 
In-111 Octreotide SPECT (where at that time CT was 
taken  as  the  reference  for  comparison)  in  detecting 
upper abdominal metastases.5 In a recent study, Ga-68 
DOTATOC PET/CT was proven to be far superior to 
In-111 DTPA-OC in the detection of NET metastases 
in the skeleton and other organs.6 In another study 
using Ga-68 DOTATOC PET, which is in full agree-
ment  with  our  own  observations,  the  accuracy  of 
Ga-68 DOTATOC PET (96%) was found to be signifi-
cantly  higher  than  that  of  CT  (75%)  and  In-111 
DOTATOC SPECT (58%) on a patient basis.7 In 32/88 
patients,  Ga-68  DOTATOC  PET  was  true  positive 
whereas SPECT results were false negative; in addi-
tion, PET was able to detect more lesions than SPECT 
and CT. The authors also reported that for the staging 
of patients, PET was better than CT or SPECT as it 
picked  up  more  lesions  in  lymph  nodes,  liver  and 
bones. Overall, PET provided clinically relevant addi-
tional information in 14% of the patients when com-
pared to SPECT and in 21% of patients when com-
pared to CT. Kowalski et al. described the superiority 
of Ga-68 DOTATOC PET over In-111 octreotide scan, 
especially in detecting small tumors or tumors bear-
ing  only  a  low  density  of  SSTRs.12  In  a  larger  sub-
group  of  patients  (n  =  90)  with  pathologically  con-
firmed  NETs,  a  comparison  between  Ga-68 
DOTANOC PET/CT and conventional imaging (CI - 
CT and endoscopic ultrasound) showed the superior-
ity  of  PET/CT  over  CI.8  Our  experience  after  more 
than  5,800  SSTR  PET/CT  studies  performed  at  the 
Zentralklinik Bad Berka is that Ga-68 SSTR PET is able 
to  detect  many  lesions  which  are  not  routinely  de-
tected  by  CT,  magnetic  resonance  imaging  (MRI), 
skeletal scintigraphy or ultrasonography (Fig. 1).  
Ga-68 SSTR PET/CT provides a “one-stop shop” 
whole-body investigation of NETs (Fig. 2) for staging, 
including  evaluation  of  liver,  lymph  nodes,  bone, 
lung, brain and other possible tumor sites. Apart from 
gastroenteropancreatic  NETs,  SSTR  PET/CT  with 
Ga-68 labeled somatostatin analogs has also been en-
visaged  to  have  a  potential  role  in  small  cell  lung 
cancer as this tumor is known to express SSTRs.13,14 In 
a bi-centric study, our group has checked the role of 
SSTR PET/CT in the detection of unknown primary 
(CUP) NETs in which Ga-68 DOTANOC PET/CT was 
found to be highly superior to In-111 Octreoscan and 
can play a major role in the management of patients Theranostics 2012, 2(5) 
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with  CUP-NET.15  SSTR  PET/CT  is  particularly  of 
theranostic  value  in  the  evaluation  of  the  receptor 
status  before  peptide  receptor  radionuclide  therapy 
(PRRNT),  or  before  therapy  with  somatostatin  ana-
logs  (e.g.  octreotide  or  lanreotide)  to  determine  the 
receptor  density  semi-quantitatively  by  the  meas-
urement of SUV (Standardized Uptake Values).16 An-
other major advantage of Ga-68 SSTR PET/CT is in 
the follow up and evaluation of molecular response 
(MORE) to therapy by assessing the molecular tumor 
volume and by quantification of the SSTR density in 
vivo before and after PRRNT (Fig. 3).14 It also helps in 
re-staging, e.g. in patients with rising tumor markers 
(chromogranin A, serotonin, calcitonin, glucagon) and 
for detection of recurrences. 
Ga-68 DOTATOC PET has been found to be su-
perior  to  F-18  FDG  PET  in  the  detection  of 
well-differentiated  NETs,  demonstrating  57/63  le-
sions in 15 patients, as compared to only 43/63 de-
tected by FDG PET.17 In malignant neural crest tumors 
(pheochromocytoma, paraganglioma, and medullary 
thyroid cancer), a direct comparison with I-123 MIBG 
imaging showed the superiority of Ga-68 DOTATATE 
PET/CT in terms of sensitivity.18 An intra-individual 
study  comparing  the  diagnostic  efficacy  of  Ga-68 
DOTANOC  and  Ga-68  DOTATATE  demonstrated 
that  Ga-68  DOTANOC  may  be  superior  to  Ga-68 
DOTATATE in certain cases.19 
Receptor PET/CT using Ga-68 labeled somato-
statin analogs enables molecular imaging of NETs and 
their metastases with very high diagnostic sensitivity 
and  specificity.  It  provides  quantitative  and  repro-
ducible data (SUV) which can be used for selecting 
patients  for  PRRNT  and  evaluation  of  therapy  re-
sponse.  Among  other  advantages  are  fast  protocol 
(60-90 min.), low radiation burden (10-12 mSv), flexi-
bility in daily use and lower cost than octreotide scin-
tigraphy. 
 
 
 
Fig. 1: Comparison between Ga-68 SSTR PET/CT (PET images upper row and fused PET/CT lower row), and CT (middle row) showing 
(A) liver metastasis with normal CT, (B) lymph node metastasis with inconclusive CT findings and (C) bone metastasis seen on both PET 
and CT images. Theranostics 2012, 2(5) 
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Fig. 2: Whole body “one-stop shop” diagnosis with receptor-PET/CT (A – MIP; B, C and D - PET, CT and fused images) using Ga-68 
DOTATOC showing primary neuroendocrine tumor in the ileum (B) with lymph node (C) & bone metastases (D). 
 
Fig. 3: Monitoring of molecular response to peptide receptor radionuclide therapy with Lu-177/Y-90 labeled somatostatin analogs by 
quantification of somatostatin receptor density using Ga-68 somatostatin receptor PET/CT. Theranostics 2012, 2(5) 
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The  strong  expression  of  SSTR2  by  NETs  also 
enables  PRRNT,  the  molecular  internal  radiation 
therapy of NETs. The significant points to take into 
account concerning PRRNT are patient selection, ap-
propriate choice of peptide and radionuclide, kidney 
protection  (lysine,  arginine,  gelofusine),  tumor  and 
organ  dosimetry  (post-treatment  scans)  and  moni-
toring of toxicity (follow-up). In our hospital which 
was certified as ENETS Center of Excellence in March 
2011,  a  dedicated  multidisciplinary  team  of  experi-
enced NET specialists is responsible for the manage-
ment  of  NET  patients  (over  1,000  patient  visits  per 
year).  
Patient selection for PRRNT is based on the Bad 
Berka Score (BBS) which takes into accounts the fol-
lowing clinical aspects and molecular features:  
1.  SUV  on  receptor  PET/CT  (for  referrals: 
Krenning’s score on OctreoScan) for determining SMS 
receptor density 
2.  Renal function – glomerular fil-tration rate 
(GFR)  measured  by  Tc-99m  DTPA  and  tubular 
ex-traction rate (TER) measured by Tc-99m MAG3 as 
well  as  serum  creatinine  and  blood  urea  nitrogen 
(BUN), and elimination kinetics 
3.  Hematological status (blood counts) 
4.  Liver involvement 
5.  Extra-hepatic tumor burden 
6.  Ki-67 index / tumor grade 
7.  F-18  fluorodeoxyglucose  (FDG)  PET/CT 
status  (glucose  hy-permetabolism  of 
tu-mors/metastases) 
8.  Tumor dynamics (doubling time, new le-
sions) 
9.  Karnofsky  performance  score  (KPS)  or 
ECOG scale 
10.  Weight loss 
11.  Time since first diagnosis 
12.  Functional activity of tumor 
13.  Previous therapies 
 
The therapy plan for each patient is individual-
ized. Frequent therapy cycles (4-6 and up to 8), ap-
plying low or intermediate doses of radioactivity are 
suitable  for  these  relatively  slow-growing  tumors 
(“long term low dose, not short term high dose con-
cept”).  For  kidney  protection,  patients  are  well  hy-
drated and receive an amino acid infusion containing 
lysine and arginine given intravenously for 4 hours 
beginning 30 minutes before PRRNT. Before each new 
treatment cycle, restaging is performed by morpho-
logic (CT/MRI) and molecular imaging (Ga-68 SSTR 
PET/CT, in selected cases F-18 FDG or F-18 fluoride 
PET/CT  studies  are  additionally  performed),  blood 
chemistry and tumor markers (chromogranin A, ser-
otonin, specific hormones). Renal function is serially 
determined  by  Tc-99m  MAG3  scan/TER  and  by 
Tc-99m DTPA (GFR) measurements. All data are en-
tered  in  a  prospective  structured  database  (pro-
grammed in ACCESS and containing 284 items per 
patient). Another very important aspect of personal-
ized  medicine  and  THERANOSTICS  is  dosimetry 
(Fig. 4). Estimation of tumor and normal organ doses 
(MIRD/OLINDA)  performed  after  PRRNT  (using 
Lu-177 labeled somatostatin analogs DOTATATE or 
DOTATOC)  is  important  to  ensure  that  maximum 
dose  is  delivered  to  the  tumors  and  therefore  opti-
mizing an individualized treatment protocol.20  
In  patients  with  progressive  NETs  of 
non-pancreatic origin and pancreatic NETs (pNETs), 
tumor response after a mean follow-up of 2 years was 
as follows: after 3 PRRNT cycles, complete remission 
(CR), partial remission (PR), and minor response (MR) 
were seen in 52% of patients with pNETs (and in 48% 
in  non  pancreatic  NETs);  disease  was  stabilized  in 
39% of pNETs and in 45% of patients with non pan-
creatic  NETs  (Fig.  5).  Thirty-six  patients  with  ad-
vanced disease died of progressive disease (PD). Ob-
jective  tumor  responses  (including  improvement  of 
clinical symptoms) were seen in 93% (91% pNETs) of 
the  patients.  Significant  hematological  toxicity 
(mainly  erythrocytopenia,  rarely  neutropenia,  and 
thrombocytopenia)  occurred  in  less  than  15%  of  all 
patients.  Myelodysplastic  syndrome  (MDS)  devel-
oped in 5 patients (all of them received also chemo-
therapy before). End stage renal insufficiency was not 
observed in any of the patients with normal kidney 
function  before  PRRNT.  In  most  patients  receiving 
Lu-177  DOTATATE  alone  (n  =  417  cycles),  serum 
creatinine and TER/GFR did not change significantly. 
Therefore,  the  probability  and  magnitude  of  renal 
toxicity  can  be  significantly  reduced  (or  completely 
avoided) when PRRNT is administered in fractionat-
ed  doses  in  patients  without  any  pre-existing  risk 
factors  and  under  appropriate  nephroprotection. 
Chemotherapy,  diabetes  mellitus,  hypertension, 
Hedinger’s syndrome, and cachexia were identified as 
the risk factors for nephrotoxicity after PRRNT.21 
We also have treated patients with progressive 
metastases of NETs and with a single functional kid-
ney  (24  patients).  None  of  these  patients  showed 
grade 3 or 4 nephrotoxicity. PRRNT resulted in partial 
remission in 36% and stable disease in 36% of the pa-
tients, 28% had PD. 14 had grade 1 erythrocytopenia, 
3  had  grade  1  leucocytopenia  and  3  had  grade  1 
thrombocytopenia. In 2009, we have given fraction-
ated low dose PRRNT to 2 patients on hemodialysis 
due to end-stage renal insufficiency (to the best of our 
knowledge, this was the first ever worldwide experi-Theranostics 2012, 2(5) 
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ence with such a condition). No significant hemato-
toxicity was observed in the two patients on dialyses 
and both showed a good clinical and objective thera-
py repsonse.22  
 
 
Fig. 4: The Bad Berka Dose protocol – Analysis of regions of interest around whole body, tumor and normal organs in anterior and 
posterior planar whole body post-therapy (Lu-177 DOTA-somatostatin analogs) scans at 5 time intervals (A), determination of time 
activity curves in anterior and posterior scans (B) and using the geometric mean, fitting of the time-activity curves to an exponential 
function to obtain the residence time of the radiopharmaceutical in the region of interest. 
 
Fig. 5: VIPoma patient with Verner Morrison syndrome (severe watery diarrhoea, hypokalemia), high dose octreotide (Sandostatin LAR) 
prior to PRRNT. After administration of one single cycle of 5 GBq Y-90 DOTATATE, there was no need of octreotide after 3 months, 15 
kg weight gain and significant reduction of tumor burden (partial remission. After follow up of 1 year, the liver and kidney functions were 
normal and only single liver metastasis remained. Theranostics 2012, 2(5) 
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Fig. 6: Long term effect on renal function depending on the radionuclide used for PRRNT. 
 
The  Bad  Berka  neuroendocrine  tumor  center 
(BBNETC)  group  was  the  first  also  to  use  Y-90 
DOTATATE,  and  in  a  large  patient  group,  Lu-177 
DOTATOC  in  progressive  NETs,  non-responsive  to 
octreotide/interferon treatment or chemotherapy. An 
important influence on the decision of the choice of 
radionuclide is the size of tumors. More commonly, 
patients present with tumors of various sizes and in-
homogeneous distribution of somatostatin receptors. 
The use of a combination of radionuclides Lu-177 and 
Y-90 takes this heterogeneity into account. Sequential 
administration  of  Y-90  and  Lu-177  labeled  analogs 
also  is  similarly  helpful  for  the  treatment  of  larger 
tumors, followed by treatment of smaller metastases 
respectively in further treatment cycles. The BBNETC 
group  pioneered  the  systematic  use  of  Y-90  and 
Lu-177 DOTATATE (DUO-PRRNT) in sequence and 
concurrently, as well as the intra-arterial use of Y-90 
DOTATATE  and  DOTATOC.  Lu-177  DOTATATE 
was predominantly used for small  metastases  or in 
patients with impaired renal or hematological func-
tion. Long term follow-up of up to 7 years after DUO 
PRRNT showed no significant grade 3 or grade 4 ne-
phrotoxicity  attributed  to  concurrent  or  sequential 
DUO PRRNT. The median fall in tubular extraction 
rate  (TER)  was  lesser  in  patients  undergoing  DUO 
PRRNT than in those undergoing PRRNT with Lu-177 
or Y-90 alone (Fig. 6). The results of a study by Ku-
nikowska  et  al  also  indicated  that  tandem  PRRNT 
(with  Y-90/Lu-177  DOTATATE)  provided  longer 
overall survival than with a single radioisotope (Y-90 
DOTATATE)  and  the  safety  of  both  methods  was 
comparable.23  
Thus,  in  patients  with  progressive  NETs,  frac-
tionated,  personalized  PRRNT  with  lower  doses  of 
radioactivity given over a longer period of time (Bad 
Berka  Protocol)  is  effective  even  in  advanced  cases 
and results in excellent therapeutic responses. Up to 8 
cycles of PRRNT, given over several years were tol-
erated very well by most patients. Severe hematolog-
ical and/or renal toxicity can be avoided or reduced. 
Quality of life can be significantly improved. Though 
cure is rarely possible, excellent palliation with sig-
nificant improvement of symptoms can be achieved 
by PRRNT. In addition, neoadjuvant PRRNT could be 
administered  in  cases  of  inoperable  NET  so  as  to 
render the tumor operable by inducing radiation in-
duced necrosis.24,25 
A recent analysis of 416 patients (all NET sub-
types) treated at the BBNETC showed a median over-
all  survival  from  the  time  of  first  diagnosis  of  210 
months (Rotterdam data 128 months) and a median 
survival  after  1st  PRRNT  of  59  months  (Rotterdam 
data 46 months). 26 Our experience confirms a previ-
ous report from the Rotterdam group that - compared 
with historical controls - there is a benefit in overall 
survival  from  time  of  diagnosis  of  several  years. In 
progressive  NETs,  sequential  (DUO)  or  concurrent 
(TANDEM) PRRNT with Lu-177 and Y-90 has been 
found  to  be  most  effective  (highest  CR  /  PR  /  SD 
rate).  
However, PRRNT should only be performed at 
specialized centers as NET patients need highly indi-
vidualized interdisciplinary treatment and long term Theranostics 2012, 2(5) 
 
http://www.thno.org 
444 
care.27 Use of intra-arterial PRRNT (> 50 treatments 
already performed up to now) is more effective for 
selectively targeting liver metastases and large, inop-
erable  primary  tumors.  PRRNT  can  be  effectively 
combined  with  transarterial  chemoembolization 
(TACE), radio-frequency ablation (RFA), chemother-
apy (e.g. using Capecitabine, Temazolomide or Dox-
orubicin), kinase inhibitors (e.g. Everolimus, Sunitinib 
or  Sorafenib)  or  possibly  with  antibodies  (e.g. 
Bevacizumab). 
THERANOSTICS OF NON-NETs 
A number of novel Ga-68 labeled tracers (Table 
1)  have  recently  become  available  for 
THERANOSTICS.28  This  also  includes  non-peptide 
tracers  such  as  the  biphosphonate-based  agent 
BPAMD  -  ((4-{[bis-(phosphonomethyl))  car-
bamoyl]methyl}-7,10  bis(carboxymethyl)-1,4,7,10- 
tetraazacyclododec-1-yl)acetic  acid.29  PET/CT  with 
Ga-68  BPAMD  using  the  readily-available  genera-
tor-produced radionuclide is more sensitive and pro-
vides  for  high  resolution  imaging,  with  concurrent 
whole body CT for anatomical correlation.  
The Bad Berka group was also the first to use in 
humans,  a  Ga-68  labeled  gastrin  releasing  peptide 
receptor (GRP-R) selective bombesin analogue AMBA 
(DO3A-CH2CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-
M-NH2)  and  the  GRP-R  antagonist  demobesin  for 
imaging of metastatic breast, lung and prostate can-
cers.30 Many other Ga-68 radiopharmaceuticals have 
been  used  by  our  group  as  first  in  human  studies, 
such  as  Ga-68  labeled  macroaggregates  (MAA)  for 
lung perfusion PET/CT31, Ga-68 DOTA- alpha-MSH 
(melanocyte stimulating hormone) in a patient with 
metastatic ocular melanoma32, and Ga-68 labeled af-
fibody  molecule  targeting  HER2  (human  epidermal 
growth factor receptor 2 ) 33. Our experience confirms 
that Ga-68 is a very useful, practical and affordable 
radionuclide for high resolution PET/CT imaging and 
holds great promise for the future.  
Lu-177-BPAMD has been used in patients with 
widespread,  painful  skeletal  metastases,  presenting 
with  progressive  disease  and  refractory  to  conven-
tional treatment (Fig. 7).34 Dosimetry showed that due 
to the very long half life of the radiopharmaceutical in 
the  metastases  (>80  hours),  tumor  doses  delivered 
were high, ranging from 2.4 – 209 mGy/MBq (wide 
range due to different size of the lesions). A signifi-
cant  reduction  in  osteoblastic  activity  of  the  bone 
metastases was seen on the follow up PET/CT using 
Ga-68  BPAMD  or  F-18  fluoride.  The  treatment  was 
very well tolerated by all patients without any signif-
icant acute adverse effects. There were only mild to 
moderate changes in blood cell counts, and no signif-
icant alterations in serum creatinine/BUN or other lab 
parameters were observed. The first ever Lu-177 de-
mobesin  therapy  was  also  administered  in  2009.  In 
continuum,  a  novel  GRP-R  antagonist  labeled  with 
Lu-177 was administered in a patient with metastatic 
prostate cancer. Noteworthy amongst the other ther-
apeutic radiopharmaceuticals (Table 2) is also the first 
antiangiogenic  radionuclide  therapy  using  Lu-177 
labeled RGD (arginine-glycine-aspartic acid). 35  
 
Fig. 7: Lu-177 BPAMD post-therapy planar images (posterior view) in a patient of metastatic prostate cancer at 5 time intervals for 
dosimetry, showing high uptake in skeletal metastases with high contrast and long effective half life (retention), and rapid renal clearance. Theranostics 2012, 2(5) 
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Table 1. Diagnostic radiopharmaceuticals first used at the Bad Berka neuroendocrine tumor and THERANOSTICS center 
Radiopharmaceutical  First use 
(month/year) 
Principle  Clinical indication 
Ga-68 DOTANOC  07/2004  SSTR targeting (agonist)  NETs 
* Ga-68 gastrin  12/2006  Gastrin receptor targeting  Medullary carcinoma of thyroid 
* Ga-68 AMBA  08/2006  Bombesin analogue - GRP and NMB 
receptor targeting 
Carcinomas of breast, prostate, colon 
* Ga-68 tyrosine  08/2008  Amino acid uptake by tumour cells  Brain tumors (Gliomas) 
* Ga-68 BPAMD  02/2009  Biphosphonate - Binding to hydrox-
yapatite structure of bone 
Skeletal metastases 
* Ga-68 MAA   09/2008  Mechanical trapping of MAA 
(Macroaggregated albumin) in the 
capillary bed 
Pulmonary thromboembolism, visualization of the 
perfusion pattern before selective intra-arterial 
therapy (e.g. internal radiation using Y-90 for hepatic 
metastases) 
* Ga-68 glucose  05/2009  Tumor hypermetabolism  Similar to the use of 18F-FDG in tumors 
* Ga-68 demobesin  07/2009  GRP receptor antagonist  Carcinomas of breast, prostate, colon 
* Ga-68 JR10  05/2009  SSTR targeting (antagonist)  NETs 
* Ga-68 alpha-MSH  05/2010  Cell surface receptor targeting of 
melanocytes 
Melanoma 
* Ga-68 sarabesin-6   08/2011  GRP receptor antagonist  Carcinomas of breast, prostate, colon 
* Ga-68 RGD  09/2011  Integrin/ 
alpha-v beta-3 targeting (antagonist) 
Investigation and monitoring of neoangiogenesis 
and invasiveness of cancers like breast, colon, pros-
tate, lung etc. 
* Ga-68 HER-2 affibody  12/2005  HER-2 targeting  Prognostication in carcinoma breast (investigation of 
HER-2 status before herceptin therapy) 
* Ga-68 SHAL  05/2010  Selective high affinity ligand for B-cell 
lymphoma 
B-cell Lymphoma 
* Tc-99m demobesin  11/2009  GRP receptor antagonist  Carcinomas of breast, prostate, colon 
* Scandium-44 DOTATOC  02/2009  SSTR targeting (agonist)  Pre-therapeutic dosimetry before PRRNT in NETs 
(DOTANOC - DOTA-1-Nal3-octreotide; SSTR – somatostatin receptor; NETs – neuroendocrine tumors; * - first in human study; AMBA - 
DO3A-CH2CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH2; GRP – Gastrin releasing peptide; NMB – Neuromedin B; BPAMD - 
((4-{[bis-(phosphonomethyl)) carbamoyl]methyl}-7,10 bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid; MAA – macro ag-
gregated albumin; FDG – fluorodeoxyglucose; JR 10 - somatostatin receptor antagonist (Courtesy Helmut Maecke, Basel, Switzerland); MSH 
– melanocyte stimulating hormone; RGD - arginine-glycine-aspartic acid; HER-2 – human epidermal growth factor receptor 2; SHAL – 
selective high affinity ligand; DOTATOC - DOTA-D-Phe1-Tyr3-octreotide; PRRNT – peptide receptor radionuclide therapy) 
 
Table 2. Therapeutic radiopharmaceuticals first used at Bad Berka THERANOSTICS Center 
Radiopharmaceutical  First use (month/year)  Clinical indication 
Lu-177 DOTATATE  08/2004  PRRNT in NETs 
* Combined Y-90 and Lu-177 labeled somatostatin analogs    TANDEM-PRRNT in NETs 
* Systematic use of sequential Y-90 and Lu-177 labeled 
somatostatin analogs 
  DUO-PRRNT in NETs 
* Intra-arterial Y-90 DOTATATE    Selective internal radiation therapy in NETs 
Lu-177 AMBA    Radionuclide therapy of metastatic carcinoma breast 
* Lu-177 RGD    Anti-angiogenesis therapy 
* I-131 Phenylalanine (ACD-101)  04/2009  Endoradiotherapy in brain tumor (glioma) 
* Lu-177 BPAMD  07/2009  Radionuclide therapy and pain palliation of skeletal 
metastases in carcinoma prostate 
* PRRNT with Lu-177 DOTATATE in a patient on hemodi-
alysis 
06/2009  First PRRNT in NET with end stage renal disease 
* Lu-177 demobesin  12/2009  Radionuclide therapy in carcinoma breast 
* Lu-177 sarabesin-6   04/2011  Radionuclide therapy in carcinoma prostate 
 (DOTATATE - DOTA-D-Phe1-Tyr3-Thr8-octreotide) Theranostics 2012, 2(5) 
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FUTURE PERSPECTIVES 
As we move towards personalized medicine, the 
diagnostic information obtained from PET/CT must 
be improved, i.e., by fast and routine quantification of 
lesions.  The  Bad  Berka  Molecular  Imaging  Tool 
(BBQ-MIT) has been developed by us based on the 
cognition network language (CNL), provided by De-
finiens AG (Munich,  Germany). BBQ-MIT is an au-
tomatic, user-independent routine for segregation and 
quantification  of  neoplastic  lesions  in  molecular 
PET/CT DICOM sets (Fig. 8). This prototype routine 
built on CNL for PET/CT images enables automatic 
analysis of lesions, e.g. by calculating SUV, molecular 
tumor  volume  (MTV),  molecular  tumor  diameter 
(MTD), molecular tumor index (MTI = SUV x MTD), 
whole-body and organ tumor burden and many other 
parameters. It seems especially promising for short-
ening the analysis time for reading a PET scan with 
many  tumor  lesions,  improving  reproducibility,  as 
well as increasing the sensitivity in lesion detection. 
We  firmly  believe  that  BBQ-MIT  is  a  definite  step 
forward and should set a trend towards the fast and 
accurate  analysis  of  serial  PET/CT,  allowing  moni-
toring of tumor response and assessment of therapy 
effect  early  in  the  course  of  therapy,  thus  enabling 
effective personalized patient management.  
Also  promising  prospects  in  the 
THERANOSTICS of NETs include the use of fourth 
generation peptides, SSTR antagonists (these peptides 
may be superior to agonists due to  higher receptor 
density on tumor cells), somatostatin analogs target-
ing  all  known  SSTR  subtypes  (except  SSTR4),  and 
therefore a wider tumor spectrum, and targeting of 
multiple receptors. A more accurate and truly indi-
vidualized approach to dosimetry would be with de-
velopment  of  newer  methods  for  3D  calculation  of 
dose.  Pre-therapeutic  organ  and  tumor  dosimetry 
using  receptor  PET/CT  can  be  accomplished  using 
longer  lived  positron  emitters,  e.g.  Sc-44,  Y-86  or 
Cu-64 and comparison of these results with those ob-
tained from Ga-68, are needed. The appropriate pep-
tide  and  radionuclide  for  individualized  therapy 
(“personalized  medicine”)  can  be  then  selected  by 
pre-therapeutic  measurement  of  organ  and  tumor 
doses. The first human study using the longer-lived, 
generator-derived, trivalent metallic positron emitter 
Scandium-44 (Sc-44) coupled to DOTATOC was per-
formed in Bad Berka in 2009. Sc-44 has a half life of 3.9 
hrs and is derived from a Titanium-44/Scandium-44 
generator, which has a half life of 60 years.36,37 This 
may  inspire  the  development  of  new  radiopharma-
ceuticals for covering longer imaging periods.  
 
 
Fig. 8: Example of monitoring therapeutic response by compar-
ison of pre-PRRNT (left) and post-PRRNT Ga-68 somatostatin 
receptor  PET/CT  DICOM  sets  using  BBQ-MIT,  an  automatic, 
rapid, user-independent routine for segregation and quantification 
(SUV and tumor volumes) of neoplastic lesions by determine the 
lesions’ borders. 
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